Breast Cancers Today

Breast Cancers Today features breaking news, commentary, expert interviews, and more updates to inform healthcare professionals on the latest research and best clinical practices in the breast cancer space.

HER2

TNBC

Genetics

ASCO 2025: Breast Cancers Today

Explore key insights, expert perspectives, and practice-changing research in breast cancer presented at the 2025 ASCO Annual Meeting.

Latest News

Neoadjuvant Immunity: Oncolytic Virus + Chemo Shows Promise in Early TNBC

Hatem Soliman, MDTriple-Negative Breast Cancer | June 12, 2025

TVEC plus chemo shows promise in early TNBC, boosting immune response and survival with favorable safety profile.

How AI Is Reshaping Oncology Practice: Insights From ASCO’s AI Task Force

Debra Patt, MD, PhD, MBABreast Cancer News | June 12, 2025

Dr. Patt discusses how AI is transforming oncology care, and how to implement it responsibly and effectively.

ReDiscover Trial: Novel PI3Kα Inhibitor RLY-2608 Shows Promising Safety, Efficacy

Sarah Sammons, MDHR Breast Cancer | June 12, 2025

Dr. Sammons on RLY-2608 plus fulvestrant in HR+/HER2– mBC with PIK3CA mutations: safety, efficacy, and trial updates.

HER2+ Practice-Changing Data From ASCO 2025 With Dr. Rebecca Shatsky

Rebecca Shatsky, MDHER2 Breast Cancer | June 10, 2025

Dr. Shatsky weighs DESTINY-Breast09 findings and highlights the need to balance efficacy with long-term quality of life.

Emi-Le ADC Targets B7-H4 in TNBC and Beyond: Promising Early Efficacy with Novel Payload

Erika P. Hamilton, MDTriple-Negative Breast Cancer | June 9, 2025

Emi-Le ADC shows promising activity in B7-H4–positive TNBC and endometrial cancer with a novel auristatin payload.

Shifting First-Line Strategy: Inavolisib Shows OS, PFS Gains in INAVO120 Trial

Sibylle Loibl, MDHR Breast Cancer | June 9, 2025

INAVO120 shows OS benefit with inavolisib in PIK3CA-mutated HR+/HER2– aBC, raising new considerations for first-line care.

Can We Improve Second-Line Outcomes in ESR1-Mutated mBC? Insights From ADELA

Antonio Llombart Cussac, MD, PhDHR Breast Cancer | June 11, 2025

ADELA trial explores elacestrant + everolimus for ESR1-mutated breast cancer post-CDK4/6, aiming to boost 2L outcomes.

Dr. Rebecca Shatsky on the Top Breakthroughs in TNBC at ASCO 2025

Rebecca Shatsky, MDTriple-Negative Breast Cancer | June 9, 2025

New ASCENT-04 data could shift first-line care in PD-L1+ TNBC. Dr. Rebecca Shatsky shares real-world insights from ASCO 2025.

Treating Brain and Leptomeningeal Metastases: Promising TUXEDO-3 Data with HER3-Directed ADC

Rupert Bartsch, MDHER2 Breast Cancer | June 6, 2025

HER3-DXd shows promise for CNS metastases in breast and lung cancer in the TUXEDO-3 trial, including patients with LMD.

Interpreting ASCENT-04 Findings With Dr. Sarah Tolaney

Sara Tolaney, MD, MPHTriple-Negative Breast Cancer | June 6, 2025

Sacituzumab + pembrolizumab improved PFS vs chemo in PD-L1+ TNBC in ASCENT-04, with no new safety signals.

Expert Interviews

Editorial Board

Stephanie L. Graff, MDEditor | Director of Breast Oncology, Brown University Health Cancer Institute

Rebecca Shatsky, MDEditor | Associate Professor of Medicine, Moores Cancer Center at the University of California, San Diego

Maryam Lustberg, MD, MPHEditor | Director of the Center for Breast Cancer, Smilow Cancer Hospital and Yale Cancer Center

Erika P. Hamilton, MDEditor | Director of Breast Cancer and Gynecologic Cancer Research, Sarah Cannon Research Institute

Sarah Sammons, MDEditor | Associate Director, Metastatic Breast Cancer Program, Dana-Farber Cancer Institute